04/01/2019 | Press release | Distributed by Public on 04/01/2019 02:49
Charles Gross 4/1/2019 3:10:44 AM
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that a three-member panel of the European Patent Office's (EPO) Opposition Division upheld patent EP 2 949 335 covering Teva's COPAXONE® 40mg product in Europe. The Opposition Division will issue its written underlying rationale on the decision within a few months.
COPAXONE® is a highly complex molecule for which consistentproprietary manufacturing methods are required. These determine the composition, purity and batch-to-batch consistency of COPAXONE®. The patent protects the three-times-weekly subcutaneous injection of 40 mg/mL ('40mgTIW') of glatiramer acetate for the treatment of certain forms of multiple sclerosis.
Richard Daniell, Executive Vice President Teva Europe noted: 'We are pleased that the EPO agreed with Teva's stance on the patent for COPAXONE® 40mg. Teva will continue to robustly defend the validity of the intellectual property portfolio protecting COPAXONE® 40mg.' Teva has already obtained preliminary injunction orders on the basis of European patent EP 2 949 335 to prevent the commercialization of follow on glatiramer acetate in Belgium, Denmark and Slovakia.
'We believe in the value of COPAXONE®, a treatment that has been studied extensively for more than 20years and has 2.5 million years of patient experience.We remain strongly committed in the field of neurosciences and are privileged to improve people's lives in the field of multiple sclerosis'.